Moderna (MRNA) Equity Ratio (2017 - 2026)

Moderna (MRNA) has 10 years of Equity Ratio data on file, last reported at 0.64 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.64, down 18.62% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.64 (down 18.62% YoY), and the FY2025 annual result was 0.7, down 9.05% from the prior year.
• Equity Ratio eased to 0.64 in Q1 2026 per MRNA's latest filing, from 0.7 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.79 in Q1 2025 and troughed at 0.62 in Q1 2022.
• A 5-year average of 0.73 and a median of 0.75 in 2023 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2026: Equity Ratio soared 104.55% in 2022, then decreased 18.62% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.74 in 2022, then increased by 1.67% to 0.75 in 2023, then rose by 2.52% to 0.77 in 2024, then dropped by 9.05% to 0.7 in 2025, then declined by 8.02% to 0.64 in 2026.
• Business Quant data shows MRNA's Equity Ratio at 0.64 in Q1 2026, 0.7 in Q4 2025, and 0.77 in Q3 2025.